雄激素抑制与前列腺放疗后的睾酮恢复(TRANSPORT):前列腺癌随机试验Meta分析联盟(MARCAP)五项随机试验的汇总分析
基于MARCAP联盟五项随机试验的1444例接受根治性放疗联合雄激素剥夺治疗(ADT)的前列腺癌患者个体数据,评估睾酮恢复(TR)动力学及有效去势期对肿瘤学结局的影响。TR时间随ADT时长、基线睾酮和年龄变化;有效去势期与无转移生存(MFS)的关系可能呈非线性,对接受6个月ADT者更长的有效去势期可能有帮助。
要点
- TR时间因ADT时长、基线睾酮和年龄而异,基线睾酮越高、年龄越低TR可能性越高(p<0.001)。
- 有效去势期与MFS在Cox回归中无线性关联,立方样条分析显示6个月ADT者MFS获益的最佳有效去势期为10.6个月。
- 18个月ADT者MFS获益的最佳有效去势期为18个月。
核心结论
- TR时间根据ADT时长、基线睾酮和年龄而变化。
- 有效去势期与MFS的关系可能呈非线性,对接受6个月ADT的男性更长的有效去势期可能有帮助。
研究设计与样本
- 汇总分析,获取MARCAP联盟五项随机对照试验中接受放疗联合ADT并前瞻性收集连续睾酮数据的患者个体数据。
- 共纳入1444例男性,其中115例接受4个月ADT、880例接受6个月、353例接受18个月、36例接受28个月、60例接受36个月ADT。
主要发现
- 非去势TR(>1.7 nmol/l)和非性腺功能减退TR(>8.0 nmol/l)的时间因ADT时长不同而差异很大。
- 基线睾酮较高和年龄较低与TR可能性较高相关(两者p<0.001)。
- Cox回归显示有效去势期与任何ADT时长的MFS均无线性关联。
- 立方样条分析显示,接受6个月ADT者MFS获益的最佳有效去势期为10.6个月,接受18个月ADT者为18个月。
关键数值与推荐
- 非去势TR定义为睾酮>1.7 nmol/l。
- 非性腺功能减退TR定义为睾酮>8.0 nmol/l。
- 6个月ADT者MFS获益的最佳有效去势期为10.6个月。
- 18个月ADT者MFS获益的最佳有效去势期为18个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Time to testosterone recovery (TR) following androgen deprivation therapy (ADT) with gonadotropin-releasing hormone agonists varies widely. We evaluate TR kinetics and the oncological impact of an effective castration period in patients receiving definitive radiotherapy and ADT for prostate cancer. METHODS: We obtained individual patient data from randomized controlled trials of radiotherapy with ADT and prospectively collected serial testosterone data from the MARCAP Consortium. We estimated the times to noncastrate TR (>1.7 nmol/l) and nonhypogonadal TR (>8.0 nmol/l) were estimated for each prescribed ADT duration, and developed corresponding nomograms. The association between effective castration period and metastasis-free survival (MFS) for any given ADT duration was evaluated via multivariable Cox regression. We conducted cubic spline analyses to assess nonlinear associations. KEY FINDINGS AND LIMITATIONS: We included 1444 men from five trials in the analysis, of whom 115 received 4 mo, 880 received 6 mo, 353 received 18 mo, 36 received 28 mo, and 60 received 36 mo of ADT. Times to noncastrate TR and to nonhypogonadal TR varied considerably by ADT duration. Higher baseline testosterone and lower age were associated with a higher likelihood of TR (p < 0.001 for both). Effective castration period was not linearly associated with MFS for any ADT duration on Cox regression. Cubic spline analysis revealed that the optimal effective castration period for an MFS benefit was 10.6 mo for men who received 6 mo of ADT and 18 mo for men who received 18 mo of ADT. CONCLUSIONS AND CLINICAL IMPLICATIONS: Time to TR varies according to the ADT duration, baseline testosterone, and age. The relationship between effective castration period and MFS may be nonlinear, with a longer effective castration period being helpful for men receiving 6 mo of ADT.
引用
- Ong WL, Romero T, Roy S, et al. Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. Eur Urol. 2024. PMID: 39304428. doi:10.1016/j.eururo.2024.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。